Co-Founder and CEO, Wetpaint
Vice president, chief strategy and operating officer of the Texas Medical Center
CEO and co-founder of BoostSuite
Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
The San Diego Venture Group has invited Domain Associates partner Eckard Webber and Regulas Therapeutics CEO Kleanthis Xanthopoulos to discuss how life sciences financing has changed in recent years. Inquiring minds want to know: How does royalty-based financing work at an early stage company? Should companies submit their IPO filings confidentially under the new provisions of the JOBS Act? Should companies consider an option deal as an alternative to another private round? More information and online registration is here.